• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
Cannabinoids and COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Medical Cannabis and Cannabinoids
Yazar(lar) :
Myriam El Biali , Barbara Broers , Marie Besson , Jules Demeules
Yıl :
2020
Cannabinoids and COVID-19 involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the COVID 19 pandemia. covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
Since the endocannabinoid system is involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the COVID 19 pandemia. Some data suggest that the immunomodulatory effect of cannabinoids may affect the course and severity of SARS-CoV-2 infection. Given the large number of cannabinoids consumers in the community, this commentary presents the current knowledge on the potential impact of cannabinoids and endocannabinoids on bacterial and viral infection courses namely SARS-CoV-2 disease. Practical recommendations, which can be drawn from the literature, are given.
DOI : 10.1159/000510799
Anahtar Kelimeler : sars-cov-2, covid-19, immunity, cannabinoids, endocannabinoid system
ISSN: 2504-3889
Sayfa: 1 - 5
Sınıflandırma :
2
Stand on the Same Side Against Covid – 19 Clinical Management of Covid-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Substantia
Yazar(lar) :
Lorenzo Corbetta , Leonardo M. Fabbri , Shiyue Li , Jing Li , Bin Cao , Jin Yang , Giancarlo Agnelli , Michela Giustozzi , Alberto Mantovani , Luigi Camporota , Semra Bilaçeroğlu , Adrian Rendon
Yıl :
2020
Stand on the Same Side Against Covid – 19 Clinical Management of Covid-19 Covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
This document is the direct transcription of a Webinar organized by Prof. L. Corbetta of the University of Florence on May 29th, 2020.
DOI : 10.13128/Substantia-1022
Anahtar Kelimeler : Covid-19, Clinical Management, LOTUS China Trial, Lopinavir, Ritonavir, Wuhan
ISSN: 2532-3997
Cilt: 4
Sayı: 1
Sınıflandırma :
3
Pharmacogenomics of COVID-19 therapies
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak 1:
Directory of Open Access Journals (DOAJ)
Kaynak 2:
Springer Nature
Dergi:
npj Genomic Medicine
Yazar(lar) :
Takuto Takahashi , Jasmine A. Luzum , Melanie R. Nicol , Pamala A. Jacobson
Yıl :
2020
Pharmacogenomics of COVID-19 therapies Abstract A new global pandemic of coronavirus disease 2019 ( COVID- 19) has resulted in high mortality and morbidity. In conclusion, although direct evidence in COVID- 19 patients is lacking, we identified potential actionable genetic markers in COVID- 19 therapies. Clinical studies in COVID- 19 patients are deemed warranted to assess potential roles of these markers.
Piri Tam Metin Bulucu
Kaydet
Abstract A new global pandemic of coronavirus disease 2019 (COVID-19) has resulted in high mortality and morbidity. Currently numerous drugs are under expedited investigations without well-established safety or efficacy data. Pharmacogenomics may allow individualization of these drugs thereby improving efficacy and safety. In this review, we summarized the pharmacogenomic literature available for COVID-19 drug therapies including hydroxychloroquine, chloroquine, azithromycin, remdesivir, favipiravir, ribavirin, lopinavir/ritonavir, darunavir/cobicistat, interferon beta-1b, tocilizumab, ruxolitinib, baricitinib, and corticosteroids. We searched PubMed, reviewed the Pharmacogenomics Knowledgebase (PharmGKB®) website, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, the U.S. Food and Drug Administration (FDA) pharmacogenomics information in the product labeling, and the FDA pharmacogenomics association table. We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). We also identified other variants, that are associated with adverse effects, most notable in hydroxychloroquine/chloroquine (G6PD; hemolysis), ribavirin (ITPA; hemolysis), and interferon β -1b (IRF6; liver toxicity). We also describe the complexity of the risk for QT prolongation in this setting because of additive effects of combining more than one QT-prolonging drug (i.e., hydroxychloroquine/chloroquine and azithromycin), increased concentrations of the drugs due to genetic variants, along with the risk of also combining therapy with potent inhibitors. In conclusion, although direct evidence in COVID-19 patients is lacking, we identified potential actionable genetic markers in COVID-19 therapies. Clinical studies in COVID-19 patients are deemed warranted to assess potential roles of these markers.
DOI : 10.1038/s41525-020-00143-y
ISSN: 2056-7944
Cilt: 5
Sayı: 1
Sayfa: 1 - 7
Sınıflandırma :
4
Nox2 activation in Covid-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Redox Biology
Yazar(lar) :
Francesco Violi , Alessandra Oliva , Roberto Cangemi , Giancarlo Ceccarelli , Pasquale Pignatelli , Roberto Carnevale , Vittoria Cammisotto , Miriam Lichtner , Francesco Alessandri , Massimiliano De Angelis , Maria Claudia Miele , Gabriella D'Ettorre , Franco Ruberto , Mario Venditti , Francesco Pugliese , Claudio Maria Mastroianni
Yıl :
2020
Nox2 activation in Covid-19 RNA viruses may activate Nox2, but it is unknown if this occurs in coronavirus 2019( Covid- 19). values were higher in Covid- 19 patients versus controls and in severe versus non severe Covid- 19. Oxidative stress by Nox2 activation is associated severe disease and thrombotic events in Covid- 19 patients. Covid-19
Yayıncı Web Sitesi
Kaydet
Nox2 is responsible for artery dysfunction via production of reactive oxidant species. RNA viruses may activate Nox2, but it is unknown if this occurs in coronavirus 2019(Covid-19). Nox2 activation by soluble Nox2-derived peptide(sNox2-dp) was measured in patients hospitalized for Covid-19 (n = 182) and controls (n = 91). sNox2-dp values were higher in Covid-19 patients versus controls and in severe versus non severe Covid-19. Patients with thrombotic events(n = 35,19%) had higher sNox2-dp than thrombotic event-free ones. A logistic regression analysis showed that sNox2 and coronary heart disease predicted thrombotic events. Oxidative stress by Nox2 activation is associated severe disease and thrombotic events in Covid-19 patients.
Anahtar Kelimeler : Covid-19, Nox-2, NADPH oxidase, Thrombosis
ISSN: 2213-2317
Cilt: 36
Sayfa: 101655
Sınıflandırma :
5
Pharmaceutical industry before COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Farmacja Polska
Yazar(lar) :
Krzysztof Woyna-Orlewicz , Renata Jachowicz
Yıl :
2020
Pharmaceutical industry before COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet
The 2019 CPhI Annual Report describing rankings, innovations and key trends in pharma industry is summarized. Pharmaceutical markets were assessed based on an the following indicators: growth potential, API manufacturing, innovation, competitiveness and finished product. The top three markets are USA, Germany and Japan, while China has made the largest overall improvement. Interestingly, UK demonstrated the largest growth decrease of all the markets reported. The fact is attributed to Brexit. The winner of CPhI Award was PolarDry® Electrostatic Spray Dryer. Thanks electrostatic induction applied in spraying nozzle, polar solvent is moved to the surface and non-polar ingredients into center of droplets. The most promising recent drug delivery devices were drug patches, smart dose injectors, multi-dose delivery injectable caps and smart dry powder inhalers. The most anticipated drug delivery devices are needle-free devices, wearable delivery devices, pre-filled syringes and dual chamber products as well as autoinjectors and pens. A few preselected articles were briefly summarized. Bikash Chatterjee from Pharmatech Associates described evolution of industry called Pharma 4.0. The key assumptions are gathering of data from across the global supply chain by smart sensors and devices referred to Internet of Things, the data evaluation by applying Artificial Intelligence tools and finally complete integration of databases. Mr. Girish Malhotra presented trends in global quality assurance. The following worth to be highlighted: necessity of technological improvements in manufacturing oriented on costs optimization and the highest possible drug products quality, standardization of requirements for drug products quality assessment. The regulatory agencies are oriented to enforce changes implementation by hesitant companies. D.M. Ecker and P.Seymur from BioProcess Technology Group presented „Mammalian Biomanufacutring Industry Overview”. Vicky Qing Xia described rapidly growing biotechnological market of China. M.E.Ultee paid attention on developing gene therapies market in US.
DOI : 10.32383/farmpol/125555
Anahtar Kelimeler : economic development, drug development, drug industry
Cilt: 76
Sayı: 5
Sayfa: 269 - 274
Sınıflandırma :
6
COVID-19 in hypertensive people
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Medisan
Yazar(lar) :
María Eugenia García Céspedes , Josefa Bell Castillo , Diana Enilda Romero Calzado , Niola Ferrales Biset
Yıl :
2020
COVID-19 in hypertensive people COVID- 19 is an infectious disease caused by the SARS-CoV-2 coronavirus that affects people in advanced ages of life, patients with immunodepression and With this work we wanted to update the knowledge on the COVID- 19 serious condition level in hypertensive patients and its association with the consumption covid-19
Yayıncı Web Sitesi
Kaydet
COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus that affects people in advanced ages of life, patients with immunodepression and/or chronic affections, as hypertension, in a more serious way, being the latter of great significance in the mortality due to cardiovascular and cerebrovascular diseases. With this work we wanted to update the knowledge on the COVID-19 serious condition level in hypertensive patients and its association with the consumption of antihypertensive drugs of the angiotensin converting enzyme inhibitors and antagonists of angiotensin II receptors groups. In the same way, scientific evidences are offered on the fact that hypertension is a clinical predictor of a serious condition in patients with this infectious disease, that is manifested mainly in people older than 60 years, and that the suspension in a preventive way of the mentioned antihypertensive treatments can lead to clinical instability and unfavorable results.
Anahtar Kelimeler : covid-19, coronavirus sarsu2013cov-2, hipertensión arterial, tratamiento antihipertensivo.
ISSN: 1029-3019
Cilt: 24
Sayı: 3
Sayfa: 501 - 514
Sınıflandırma :
7
COVID-19 Usurps Host Regulatory Networks
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Pharmacology
Yazar(lar) :
Colleen S. Curran , Donna R. Rivera , Jeffrey B. Kopp
Yıl :
2020
COVID-19 Usurps Host Regulatory Networks Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 ( COVID- 19). Certain characteristic COVID-associated skin, sensory, and central nervous system manifestations may also be linked to viral activation of the RAAS, complement COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 binds the angiotensin-converting enzyme 2 (ACE2) on the cell surface and this complex is internalized. ACE2 serves as an endogenous inhibitor of inflammatory signals associated with four major regulator systems: the renin-angiotensin-aldosterone system (RAAS), the complement system, the coagulation cascade, and the kallikrein-kinin system (KKS). Understanding the pathophysiological effects of SARS-CoV-2 on these pathways is needed, particularly given the current lack of proven, effective treatments. The vasoconstrictive, prothrombotic and pro-inflammatory conditions induced by SARS-CoV-2 can be ascribed, at least in part, to the activation of these intersecting physiological networks. Moreover, patients with immune deficiencies, hypertension, diabetes, coronary heart disease, and kidney disease often have altered activation of these pathways, either due to underlying disease or to medications, and may be more susceptible to SARS-CoV-2 infection. Certain characteristic COVID-associated skin, sensory, and central nervous system manifestations may also be linked to viral activation of the RAAS, complement, coagulation, and KKS pathways. Pharmacological interventions that target molecules along these pathways may be useful in mitigating symptoms and preventing organ or tissue damage. While effective anti-viral therapies are critically needed, further study of these pathways may identify effective adjunctive treatments and patients most likely to benefit.
DOI : 10.3389/fphar.2020.01278
Anahtar Kelimeler : SARS-CoV-2, renin-angiotensin-aldosterone system, COVID-19, pharmacotherapy, angiotensin II, bradykinin
ISSN: 1663-9812
Cilt: 11
Sınıflandırma :
8
COVID-19 and molecular hydrogen inhalation
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Therapeutic Advances in Respiratory Disease
Yazar(lar) :
Sergej M. Ostojic
Yıl :
2020
COVID-19 and molecular hydrogen inhalation
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
DOI : 10.1177/1753466620951051
Cilt: 14
Sınıflandırma :
9
NSAIDs for COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Pharmacy Today
Yayıncı:
Elsevier
Yazar(lar) :
Mary Warner
Yıl :
2020
NSAIDs for COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1016/j.ptdy.2020.04.006
ISSN: 1042-0991
Sayı: 5
Cilt: 26
Sayfa: 14
Sınıflandırma :
10
Inhaled NO and COVID‐19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
British Journal of Pharmacology
Yazar(lar) :
Louis J. Ignarro
Konu :
Pharmacology
Yıl :
2020
Inhaled NO and COVID‐19
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1111/bph.15085
ISSN: 0007-1188
Sayı: 16
Cilt: 177
Sayfa: 3848-3849
Sınıflandırma :
11
Can COVID-19 present unusual GI symptoms?
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of Microbiology, Immunology and Infection
Yazar(lar) :
Ahmad Hormati , Alireza Shahhamzeh , Mahboubeh Afifian , Fatemeh Khodadust , Sajjad Ahmadpour
Yıl :
2020
Can COVID-19 present unusual GI symptoms? COVID-19
Yayıncı Web Sitesi
Kaydet
Anahtar Kelimeler : COVID-19, Gastrointestinal disorder, Pneumonia, Real-time reverse-transcriptase polymerase chain reaction
ISSN: 1684-1182
Cilt: 53
Sayı: 3
Sayfa: 384 - 385
Sınıflandırma :
12
Pharmacist's perspective on HCQ treatment of COVID‐19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Kaohsiung Journal of Medical Sciences
Yazar(lar) :
Yau2010Ling Wang , Shihu2010Han Wang , Aiu2010Yu Yang
Yıl :
2020
Pharmacist's perspective on HCQ treatment of COVID‐19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
DOI : 10.1002/kjm2.12249
Cilt: 36
Sayı: 8
Sayfa: 660 - 660
Sınıflandırma :
13
COVID-19: Therapeutics and Their Toxicities
Derleme Makalesi

Derleme Makalesi
Open Access
Kaynak :
Springer Link
Dergi:
Journal of Medical Toxicology
Yayıncı:
Springer Link
Yazar(lar) :
Michael A. Chary , Alexander F. Barbuto , Sudeh Izadmehr , Bryan D. Hayes , Michele M. Burns
Konu :
harmacology, Biomedicine
Yıl :
2020
COVID-19: Therapeutics and Their Toxicities SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID- 19 pandemic. There is no current standard of care. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID- 19. Here, we review the use, mechanism of action, and toxicity of proposed COVID- 19 therapeutics. COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.
DOI : 10.1007/s13181-020-00777-5
Anahtar Kelimeler : COVID-19, SARS-CoV-2, Toxicity, Pandemic, Therapeutic
ISSN: 1937-6995
Cilt: 16
Sayı: 3
Sayfa: 284-294
Sınıflandırma :
14
Potential of Flavonoid-Inspired Phytomedicines against COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Molecules
Yazar(lar) :
Wilfred Ngwa , Rajiv Kumar , Daryl Thompson , William Lyerly , Roscoe Moore , Terry-Elinor Reid , Henry Lowe , Ngeh Toyang
Yıl :
2020
Potential of Flavonoid-Inspired Phytomedicines against COVID-19 Here, we report on flavonoid phytomedicines with potential for development into prophylactics or therapeutics against coronavirus disease 2019 ( COVID- 19 spike protein, helicase, and protease sites on the ACE2 receptor used by the severe acute respiratory syndrome coronavirus 2 to infect cells and cause COVID - 19. COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
Flavonoids are widely used as phytomedicines. Here, we report on flavonoid phytomedicines with potential for development into prophylactics or therapeutics against coronavirus disease 2019 (COVID-19). These flavonoid-based phytomedicines include: caflanone, Equivir, hesperetin, myricetin, and Linebacker. Our in silico studies show that these flavonoid-based molecules can bind with high affinity to the spike protein, helicase, and protease sites on the ACE2 receptor used by the severe acute respiratory syndrome coronavirus 2 to infect cells and cause COVID-19. Meanwhile, in vitro studies show potential of caflanone to inhibit virus entry factors including, ABL-2, cathepsin L, cytokines (IL-1β, IL-6, IL-8, Mip-1α, TNF-α), and PI4Kiiiβ as well as AXL-2, which facilitates mother-to-fetus transmission of coronavirus. The potential for the use of smart drug delivery technologies like nanoparticle drones loaded with these phytomedicines to overcome bioavailability limitations and improve therapeutic efficacy are discussed.
DOI : 10.3390/molecules25112707
Anahtar Kelimeler : flavonoids and their derivatives, phytomedicine, COVID-19, SARS-COV-2, smart nanoparticles
ISSN: 1420-3049
Cilt: 25
Sayı: 2707
Sayfa: 2707
Sınıflandırma :
15
COVID-19 and RAS: Unravelling an Unclear Relationship
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
International Journal of Molecular Sciences
Yazar(lar) :
Damiano Du2019Ardes , Andrea Boccatonda , Ilaria Rossi , Maria Teresa Guagnano , Francesca Santilli , Francesco Cipollone , Marco Bucci
Yıl :
2020
COVID-19 and RAS: Unravelling an Unclear Relationship angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease ( COVID - 19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting. COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
The renin-angiotensin system (RAS) plays a main role in regulating blood pressure and electrolyte and liquid balance. Previous evidence suggests that RAS may represent an important target for the treatment of lung pathologies, especially for acute respiratory distress syndrome and chronic fibrotic disease. The scientific community has recently focused its attention on angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (COVID-19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting.
DOI : 10.3390/ijms21083003
Anahtar Kelimeler : COVID-19, SARS-CoV-2
Cilt: 21
Sayı: 3003
Sayfa: 3003
Sınıflandırma :
16
Use Of Succulent Bio Medicines To Control COVID 19
e-Kitap

e-Kitap
Open Access
Kaynak :
Internet Archive Books
Dergi:
Internet Archive
Yayıncı:
Internet Archive
Yazar(lar) :
Dr Shibabrata Pattanayak
Yıl :
2020
Use Of Succulent Bio Medicines To Control COVID 19 some digestible capsular materials of biological origin without addition of any synthetic chemical and may be used as preventive oral medicines against COVID - 19.
Yayıncı Web Sitesi
Tam Metin
Kaydet
Use of succulent bio-medicines and other succulent bio-healthcare products can bring a dramatic change in initiation, progression as well as expression of symptoms of various diseases among individuals. Succulent parts of some effective medicinal plants in the form of paste or pressure extract can be covered by some digestible capsular materials of biological origin without addition of any synthetic chemical and may be used as preventive oral medicines against COVID-19. Plants having ethnomedicinal reports of having strong immunomodulation and antioxidation activities and plants having role in protection of respiratory organs may be selected for such use to strengthen the immunity power of the people to become refractory to the viral infections. Name of such medicinal plants with relevant parts and previous reports on their related activities, discussion of various steps related with preparation of a design for efficacy based study on the medicines and their dose determination; production, marketing and transport of these medicines up to the patient level; searching of answer of the questions raised against such herbal medicines and discussion of pros and cons of the use of such medicines are added in this book. A brief analysis of possible mechanism of actions of the succulent bio-medicines is also included in this book. [ISBN: 978-93-5407-265-9]
17
Sedating ventilated COVID-19 patients with inhalational anesthetic drugs
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
EBioMedicine
Yazar(lar) :
Beverley A. Orser , Dian-Shi Wang , Wei-Yang Lu
Yıl :
2020
Sedating ventilated COVID-19 patients with inhalational anesthetic drugs
Yayıncı Web Sitesi
Kaydet
ISSN: 2352-3964
Cilt: 55
Sayfa:
Sınıflandırma :
18
The Novel Aspirin As Breakthrough Drug For COVID 19
e-Kitap

e-Kitap
Open Access
Kaynak :
Internet Archive Books
Dergi:
Internet Archive
Yayıncı:
Internet Archive
Yazar(lar) :
Iberoamerican Journal of Medicine
Yıl :
2020
The Novel Aspirin As Breakthrough Drug For COVID 19 - 19 patients. Besides, the most wanted is The RECOVERY II (Randomized Evaluation of COVID- 19 Therapy II) trial to be established as a randomized clinical trial to test the effectiveness of low-dose Aspirin as an anti-inflammatory and antithrombotic treatment in COVID- 19 patients.
Yayıncı Web Sitesi
Tam Metin
Kaydet
Introduction: Aspirin has justifiably been called the first miracle drug. In this article, we highlight the history of Aspirin, a novel mechanism of action, and its use in cardiovascular and other diseases. Also included is a brief statement of emerging new applications. Objective: We highlight principal mechanisms by which Aspirin inhibits acute inflammation and alters platelet-biology; therefore, hypothesized that Aspirin might prove highly beneficial as a novel therapeutic drug for combating severe acute inflammation and thrombosis associated with the cytokine storm in COVID -19 patients. The communiqué also suggests possible strategies for maximizing the gain of Aspirin as a wonder-drug of the future. Discussion: Interestingly, some fascinating studies demonstrated Aspirin's superior benefits with dangerous side effects. Aspirin inhibits COX-1 (cyclooxygenase-1). Its impact on COX-2 is more delicate because it “turns off” COX-2's production of prostaglandins but “switches on” the enzymatic ability to produce novel protective lipid mediators. The established mechanism of action of Aspirin is the inhibition of prostaglandin synthesis. However, further evidence showed that aspirin-elicited nitric oxide exerts anti-inflammatory effects in the microcirculation by inhibiting leukocyte– endothelium interactions. Interestingly, aspirin-triggered lipoxin formation may provide a novel mechanism underlying Aspirin's clinical benefits. Interestingly, Aspirin reduces the risk of a cardiovascular event by about 30 percent. Also, Aspirin has been associated with a reduced risk of colorectal cancer, and possibly a few other digestive tract cancers. Conclusion: The current emerging interest is to conduct further study to provide evidence for Aspirin as the novel therapeutic drug for combating severe acute inflammation and thrombosis associated with the cytokine storm in COVID-19 patients. Besides, the most wanted is The RECOVERY II (Randomized Evaluation of COVID-19 Therapy II) trial to be established as a randomized clinical trial to test the effectiveness of low-dose Aspirin as an anti-inflammatory and antithrombotic treatment in COVID-19 patients.
19
Angiotensin receptor blockers and COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Pharmacological Research
Yayıncı:
Elsevier
Yazar(lar) :
Juan M. Saavedra
Yıl :
2020
Angiotensin receptor blockers and COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1016/j.phrs.2020.104832
ISSN: 1043-6618
Cilt: 156
Sayfa: 104832
Sınıflandırma :
20
COVID-19, myocardial edema and dexamethasone
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Medical Hypotheses
Yayıncı:
Elsevier
Yazar(lar) :
Moezedin Javad Rafiee , Faranak Babaki Fard , Matthias G. Friedrich
Yıl :
2020
COVID-19, myocardial edema and dexamethasone
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1016/j.mehy.2020.110307
ISSN: 0306-9877
Cilt: 145
Sayfa: 110307
Sınıflandırma :
21
Dental procedure aerosols and COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
The Lancet Infectious Diseases
Yayıncı:
Elsevier
Yazar(lar) :
Joel B Epstein , Kenneth Chow , Richard Mathias
Yıl :
2020
Dental procedure aerosols and COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1016/s1473-3099(20)30636-8
ISSN: 1473-3099

Sınıflandırma :
22
Therapeutic status of hydroxychloroquine in COVID-19: A review
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of Anaesthesiology Clinical Pharmacology
Yazar(lar) :
Kirandeep Kaur , Sandeep Kaushal , Ishita Gupta Kaushal
Yıl :
2020
Therapeutic status of hydroxychloroquine in COVID-19: A review In the present pandemic of coronavirus disease ( COVID)-2019, the drug is being repurposed, based on its in vitro evidence of efficacy against coronavirus - 19. In the current scenario, recommendations from Indian Council of Medical Research for use of HCQ in the prophylaxis of COVID- 19 are being followed. covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
Hydroxychloroquine (HCQ), a 4-aminoquinoline, is used worldwide mainly for its role in management of malaria and rheumatoid arthritis. In the present pandemic of coronavirus disease (COVID)-2019, the drug is being repurposed, based on its in vitro evidence of efficacy against coronavirus. There has been a lot of information, for and against the drug, and this review is an effort to bring forth the evidence and current understanding regarding role of HCQ in COVID-19. Clinical studies, case reports, and in vitro studies have generated conflicting results. There are concerns for use of HCQ because of the variable results and the known adverse effects like QT prolongation and hypoglycemia. In the current scenario, recommendations from Indian Council of Medical Research for use of HCQ in the prophylaxis of COVID-19 are being followed.
DOI : 10.4103/joacp.JOACP_313_20
Anahtar Kelimeler : covid-19, hydroxychloroquine, repurposing
Cilt: 36
Sayı: 5
Sayfa: 160 - 165
Sınıflandırma :
23
Dexamethasone nanomedicines for COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Springer Nature
Dergi:
Nature Nanotechnology
Yayıncı:
Springer Nature
Yazar(lar) :
Twan Lammers , Alexandros Marios Sofias , Roy van der Meel , Raymond Schiffelers , Gert Storm , Frank Tacke , Steffen Koschmieder , Tim H. Brümmendorf , Fabian Kiessling , Josbert M. Metselaar
Konu :
Drug delivery, Nanoparticles, Virology
Yıl :
2020
Dexamethasone nanomedicines for COVID-19 Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti- COVID- 19 treatment efficacy by targeting
Yayıncı Web Sitesi
Tam Metin
Kaydet
Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.
DOI : 10.1038/s41565-020-0752-z
ISSN: 1748-3395
Cilt: 15
Sayı: 8
Sayfa: 622-624
Sınıflandırma :
24
Demand for potentially hazardous COVID-19 treatments
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Springer Link
Dergi:
Reactions Weekly
Yayıncı:
Springer Link
Konu :
Drug Safety and Pharmacovigilance, Pharmacology
Yıl :
2020
Demand for potentially hazardous COVID-19 treatments
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1007/s40278-020-78203-x
ISSN: 1179-2051
Cilt: 1803
Sayı: 1
Sayfa: 9-9
Sınıflandırma :
25
Prophylactic Recommendation for Healthcare Workers in COVID-19 Pandemic
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Advanced Journal of Emergency Medicine
Yazar(lar) :
Guitti Pourdowlat , Parnaz Panahi , Parichehr Pooransari , Fariba Ghorbani
Yıl :
2020
Prophylactic Recommendation for Healthcare Workers in COVID-19 Pandemic During COVID- 19 pandemic, it seems that healthcare workers (HWs) are more prone to the infection than general population. So we have to improve protection and plan additional arrangements against COVID- 19. Finally, the rate and severity of COVID- 19 infections are compared.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
During COVID-19 pandemic, it seems that healthcare workers (HWs) are more prone to the infection than general population. Indeed, a high viral load atmosphere and infected medical equipment are sources for spreading the disease. Many HWs should care for critically ill COVID-19 patients in the intensive care units (ICUs) which are one of the most contaminated areas. However, despite the adequate protections, HWs are still exposed to the coronavirus. Moreover, some procedures such as tracheal intubation increase the risk of infection. Overall, the probability of contamination in HWs is three times more than that of other people. According to Keshavan et al., about 3300 Chinese HWs have been infected by COVID-19, with a mortality rate of 0.4%. In Iran, we have a large number of affected HWs, with 69 registered deaths until late March 2020. Most of them were young with no previous medical history. So we have to improve protection and plan additional arrangements against COVID-19. There are several mechanisms for the antiviral activity of hydroxychloroquine. This drug is a weak base that concentrates on the intracellular sections including endosome and lysosome; so, viral replication in the phase of fusion and uncoating will be stopped. Also, hydroxychloroquine can change the ACE2 glycosylation and inhibits both S-protein binding and phagocytosis. The last mechanism would be the suppressing effect on cytokine production and the immunomodulatory effect of the drug. Based on in-vitro studies of chloroquine on SARS-CoV-1, its effective role as a prophylactic agent and a post-infection treatment has been raised. According to another cell-culture study, the preventive effect of the drug is estimated to be 24 hours before and 5 hours after the contamination. The weekly dose of 500 mg chloroquine, which is used for malaria prophylaxis, will result in a concentration below the EC50, which is not enough for inhibition of the novel coronavirus. But the minimum dosage, which is used for rheumatoid arthritis treatment (250mg daily) will result in plasma concentrations higher than EC50, which may be sufficient in this regard. Regarding this pharmacokinetics and in-vitro investigations a double-blind, randomized, placebo-controlled trial using chloroquine as a prophylactic agent for SARS-CoV-2 infection is ongoing. The recommended dose is a loading dose of 10 mg/kg from base drug followed by 150 mg daily (250 mg chloroquine phosphate salt). Subsequently, the number of infected patients will be assessed after 3 months. Another running clinical trial is a phase III triple blinded one employing hydroxychloroquine with 200mg daily dose for 60 days and the outcome as well as the rate of symptomatic infected patients will be evaluated. There is also another ongoing study on hydroxychloroquine as a COVID-19 post-exposure prophylactic agent prescribed within 3 days of either a HWs or household contact. The recommended dose is 800mg once, followed by 600 mg during 6 to 8 hours, then 600mg once a day for 4 consecutive days. Finally, the rate and severity of COVID-19 infections are compared. The study could probably show that 200-400mg of hydroxychloroquine per day is a reasonable prophylactic regimen for the exposed HWs. To be more precise, our experience on the rheumatologic patients who tool 200 mg per day hydroxychloroquine, as well as the medical workers who received the same dose for prophylaxis against the novel coronavirus showed that hydroxychloroquine with a 200 mg/day dose can have a relative prophylactic effect on COVID-19. According to our data, the few cases who received 200mg of hydroxychloroquine per day, showed mild to moderate symptoms with no severe manifestations. However, the prophylactic dose of 400mg per day may be accompanied by some drug interactions and adverse effects in the long term; so 200mg of hydroxychloroquine is a rational prophylactic dose for practitioners who are exposed to the high viral load environment.
DOI : 10.22114/ajem.v0i0.362
ISSN: 2588-400X
Sınıflandırma :
26
Objective Olfactory Findings in Hospitalized Severe COVID-19 Patients
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Pathogens
Yazar(lar) :
Jerome R. Lechien , Morgane Ducarme , Sammy Place , Carlos M. Chiesa-Estomba , Mohamad Khalife , Giacomo De Riu , Luigi Angelo Vaira , Christophe de Terwangne , Shahram Machayekhi , Arnaud Marchant , Fabrice Journe , Sven Saussez
Yıl :
2020
Objective Olfactory Findings in Hospitalized Severe COVID-19 Patients Methods: Severe COVID- 19 patients with self-reported SLS were recruited at hospitalization discharge. Conclusion: The prevalence of SLS in severe COVID- 19 patients appears to be lower than previously estimated in mild-to-moderate COVID- 19 forms. Future comparative studies are needed to explore the predictive value of SLS for COVID- 19 severity. COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
Objective: We investigate the prevalence of the self-reported and objective sudden loss of smell (SLS) in patients with severe coronavirus disease 2019 (COVID-19). Methods: Severe COVID-19 patients with self-reported SLS were recruited at hospitalization discharge. Epidemiological and clinical data were collected. The Sino-nasal Outcome Test-22 (SNOT-22) was used to evaluate rhinological complaints. Subjective olfactory and gustatory functions were assessed with the National Health and Nutrition Examination Survey (NHNES). Objective SLS was evaluated using psychophysical tests. Potential associations between olfactory evaluation and the clinical outcomes (duration of hospitalization; admission biology; one month serology (IgG), and chest computed tomography findings) were studied. Results: Forty-seven patients completed the study (25 females). Subjectively, eighteen (38.3%) individuals self-reported subjective partial or total SLS. Among them, only three and four were anosmic and hyposmic, respectively (38.9%). Considering the objective evaluation in the entire cohort, the prevalence of SLS was 21.3%. Elderly patients and those with diabetes had lower objective olfactory evaluation results than young and non-diabetic individuals. Conclusion: The prevalence of SLS in severe COVID-19 patients appears to be lower than previously estimated in mild-to-moderate COVID-19 forms. Future comparative studies are needed to explore the predictive value of SLS for COVID-19 severity.
DOI : 10.3390/pathogens9080627
Anahtar Kelimeler : smell, olfactory, COVID-19, coronavirus, severe, anosmia
ISSN: 2076-0817
Cilt: 9
Sayı: 627
Sayfa: 627
Sınıflandırma :
27
COVID-19 and Diabetes: The Importance of Controlling RAGE
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Endocrinology
Yazar(lar) :
Ernestina M. De Francesco , Veronica Vella , Antonino Belfiore
Yıl :
2020
COVID-19 and Diabetes: The Importance of Controlling RAGE COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet
DOI : 10.3389/fendo.2020.00526
Anahtar Kelimeler : COVID-19, diabetes, RAGE (receptor for advanced glycation end products), HMGB-1 (high mobility group box 1), pneumonia, coagulation disorders
ISSN: 1664-2392
Cilt: 11
Sınıflandırma :
28
International Society of Pharmacovigilance: COVID-19 role
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Springer Link
Dergi:
Reactions Weekly
Yayıncı:
Springer Link
Konu :
Drug Safety and Pharmacovigilance, Pharmacology
Yıl :
2020
International Society of Pharmacovigilance: COVID-19 role
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1007/s40278-020-78437-3
ISSN: 1179-2051
Cilt: 1804
Sayı: 1
Sayfa: 8-8
Sınıflandırma :
29
Cyclosporine and COVID‐19: Risk or favorable?
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
American Journal of Transplantation
Yazar(lar) :
Nadia Nicholine Poulsen , Albrecht Brunn , Mads Hornum , Martin Blomberg Jensen
Konu :
Immunology and Allergy, Pharmacology (medical), Transplantation
Yıl :
2020
Cyclosporine and COVID‐19: Risk or favorable?
Yayıncı Web Sitesi
Tam Metin
Kaydet
DOI : 10.1111/ajt.16250
ISSN: 1600-6135
Sayı: 11
Cilt: 20
Sayfa: 2975-2982
Sınıflandırma :

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler